Articles

UofT Libraries is getting a new library services platform in January 2021.
Learn more about the change.

Search Articles

Advanced search
Help

Catalogue

Articles

Databases

X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (17897) 17897
Book Chapter (79) 79
Dissertation (31) 31
Conference Proceeding (28) 28
Magazine Article (22) 22
Book / eBook (11) 11
Newspaper Article (9) 9
Publication (6) 6
Book Review (2) 2
Web Resource (2) 2
Government Document (1) 1
Journal / eJournal (1) 1
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
science & technology (7824) 7824
humans (6913) 6913
life sciences & biomedicine (6666) 6666
pyrazine derivatives (4855) 4855
pyrazines - pharmacology (4633) 4633
animals (4143) 4143
male (4029) 4029
bortezomib (3906) 3906
pyrazines - therapeutic use (3109) 3109
female (2980) 2980
biological and medical sciences (2657) 2657
medical sciences (2230) 2230
middle aged (2086) 2086
pyrazines - administration & dosage (2045) 2045
chemistry (1857) 1857
oncology (1835) 1835
aged (1600) 1600
adult (1581) 1581
physical sciences (1566) 1566
boronic acids - therapeutic use (1538) 1538
pyrazines (1478) 1478
boronic acids - pharmacology (1477) 1477
multiple myeloma - drug therapy (1477) 1477
rats (1468) 1468
pharmacology & pharmacy (1413) 1413
pyrazines - chemistry (1404) 1404
mice (1395) 1395
boronic acids - administration & dosage (1235) 1235
hematology (1192) 1192
ring closure reactions (1185) 1185
pharmacology. drug treatments (1173) 1173
pyrazines - adverse effects (1096) 1096
cell line, tumor (1092) 1092
pyrazine (1040) 1040
antineoplastic agents - therapeutic use (1031) 1031
treatment outcome (1031) 1031
antineoplastic agents - pharmacology (1010) 1010
multiple myeloma (964) 964
apoptosis - drug effects (932) 932
antineoplastic combined chemotherapy protocols - therapeutic use (892) 892
biochemistry & molecular biology (876) 876
dose-response relationship, drug (845) 845
analysis (842) 842
sitagliptin phosphate (778) 778
pyrazines - chemical synthesis (725) 725
apoptosis (683) 683
boronic acids - adverse effects (671) 671
proteasome inhibitors (657) 657
research (638) 638
cancer (636) 636
abridged index medicus (612) 612
tumors (595) 595
rats, sprague-dawley (575) 575
pharmacology, medicinal chemistry, vaccines, serums (568) 568
antineoplastic agents (556) 556
care and treatment (553) 553
fundamental and applied biological sciences. psychology (553) 553
structure-activity relationship (545) 545
diabetes mellitus, type 2 - drug therapy (541) 541
molecular structure (540) 540
heterocyclic compounds (528) 528
time factors (528) 528
hematologic and hematopoietic diseases (506) 506
pyrazines - metabolism (494) 494
drug therapy, combination (477) 477
protease inhibitors - pharmacology (471) 471
aged, 80 and over (470) 470
cell proliferation - drug effects (467) 467
chemistry, multidisciplinary (466) 466
triazoles - therapeutic use (460) 460
multiple myeloma - pathology (456) 456
leukemias. malignant lymphomas. malignant reticulosis. myelofibrosis (449) 449
protease inhibitors - therapeutic use (448) 448
dexamethasone - administration & dosage (443) 443
endocrinology & metabolism (431) 431
pyrazines - pharmacokinetics (426) 426
drug synergism (422) 422
cell biology (409) 409
thalidomide - analogs & derivatives (409) 409
chemotherapy (407) 407
antineoplastic agents - adverse effects (406) 406
in vitro techniques (405) 405
clinical trials as topic (404) 404
drug therapy (399) 399
immunopathology (399) 399
immunodeficiencies. immunoglobulinopathies (392) 392
immunoglobulinopathies (391) 391
proteins (382) 382
organic chemistry (373) 373
hypoglycemic agents - therapeutic use (367) 367
chemistry, medicinal (361) 361
proteasome endopeptidase complex - metabolism (357) 357
antineoplastic agents - administration & dosage (356) 356
disease models, animal (356) 356
thalidomide - administration & dosage (348) 348
medicine & public health (345) 345
cells, cultured (339) 339
food science & technology (337) 337
health aspects (334) 334
pyridine derivatives (333) 333
more...
Library Location Library Location
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (17180) 17180
Chinese (480) 480
Japanese (282) 282
German (165) 165
French (155) 155
Italian (148) 148
Russian (67) 67
Spanish (49) 49
Polish (48) 48
Czech (28) 28
Portuguese (20) 20
Hungarian (14) 14
Dutch (11) 11
Danish (7) 7
Swedish (7) 7
Korean (6) 6
Slovak (5) 5
Norwegian (4) 4
Turkish (4) 4
Hebrew (3) 3
Finnish (2) 2
Romanian (2) 2
Persian (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


1. Full Text Superiority of bortezomib, thalidomide, and dexamethasone (VTD) as induction pretransplantation therapy in multiple myeloma: A randomized phase 3 PETHEMA/GEM study
by Rosiñol, Laura and Oriol, Albert and Teruel, Ana Isabel and Hernández, Dolores and López-Jiménez, Javier and De La Rubia, Javier and Granell, Miquel and Besalduch, Joan and Palomera, Luis and González, Yolanda and Etxebeste, Ma. Asunción and Díaz-Mediavilla, Joaquín and Hernández, Miguel T and De Arriba, Felipe and Gutiérrez, Norma C and Martín-Ramos, Ma. Luisa and Cibeira, Ma. Teresa and Mateos, Ma. Victoria and Martínez, Joaquín and Alegre, Adrián and Lahuerta, Juan José and San Miguel, Jesús and Bladé, Joan and Programa Estudio & Terapeutica Hem and Programa para el Estudio y la Terapéutica de las Hemopatías Malignas/Grupo Español de Mieloma (PETHEMA/GEM) group
Blood, ISSN 0006-4971, 08/2012, Volume 120, Issue 8, pp. 1589 - 1596
Life Sciences & Biomedicine | Hematology | Science & Technology | Hematologic and hematopoietic diseases | Immunopathology | Leukemias. Malignant lymphomas. Malignant reticulosis. Myelofibrosis | Biological and medical sciences | Immunoglobulinopathies | Medical sciences | Immunodeficiencies. Immunoglobulinopathies | Boronic Acids - toxicity | Antineoplastic Combined Chemotherapy Protocols - administration & dosage | Humans | Middle Aged | Pyrazines - administration & dosage | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Boronic Acids - adverse effects | Dexamethasone - adverse effects | Dexamethasone - toxicity | Induction Chemotherapy | Male | Transplantation, Autologous | Antineoplastic Agents - therapeutic use | Pyrazines - therapeutic use | Antineoplastic Agents - administration & dosage | Boronic Acids - therapeutic use | Antineoplastic Agents - toxicity | Multiple Myeloma - therapy | Pyrazines - toxicity | Antineoplastic Agents - adverse effects | Female | Boronic Acids - administration & dosage | Thalidomide - adverse effects | Bortezomib | Dexamethasone - administration & dosage | Multiple Myeloma - diagnosis | Thalidomide - administration & dosage | Thalidomide - toxicity | Antineoplastic Combined Chemotherapy Protocols - toxicity | Disease-Free Survival | Dexamethasone - therapeutic use | Multiple Myeloma - pathology | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Pyrazines - adverse effects | Stem Cells - drug effects | Stem Cells - pathology | Aged | Hematopoietic Stem Cell Transplantation - methods | Thalidomide - therapeutic use | Index Medicus | Abridged Index Medicus
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
2. Full Text Allosteric Inhibition of SHP2: Identification of a Potent, Selective, and Orally Efficacious Phosphatase Inhibitor
by Garcia Fortanet, Jorge and Chen, Christine Hiu-Tung and Chen, Ying-Nan P and Chen, Zhouliang and Deng, Zhan and Firestone, Brant and Fekkes, Peter and Fodor, Michelle and Fortin, Pascal D and Fridrich, Cary and Grunenfelder, Denise and Ho, Samuel and Kang, Zhao B and Karki, Rajesh and Kato, Mitsunori and Keen, Nick and LaBonte, Laura R and Larrow, Jay and Lenoir, Francois and Liu, Gang and Liu, Shumei and Lombardo, Franco and Majumdar, Dyuti and Meyer, Matthew J and Palermo, Mark and Perez, Lawrence and Pu, Minying and Ramsey, Timothy and Sellers, William R and Shultz, Michael D and Stams, Travis and Towler, Christopher and Wang, Ping and Williams, Sarah L and Zhang, Ji-Hu and LaMarche, Matthew J and Argonne National Lab. (ANL), Argonne, IL (United States)
Journal of medicinal chemistry, ISSN 0022-2623, 09/2016, Volume 59, Issue 17, pp. 7773 - 7782
Neoplasm Transplantation | Pyrimidines - chemical synthesis | Allosteric Regulation | Antineoplastic Agents - chemical synthesis | Humans | Crystallography, X-Ray | Male | Structure-Activity Relationship | Pyrimidines - chemistry | Heterografts | Piperidines - pharmacology | Drug Design | Female | Piperidines - pharmacokinetics | Antineoplastic Agents - pharmacokinetics | Antineoplastic Agents - pharmacology | Piperidines - chemistry | Administration, Oral | Mice, Inbred C57BL | Protein Tyrosine Phosphatase, Non-Receptor Type 11 - antagonists & inhibitors | Models, Molecular | Protein Tyrosine Phosphatase, Non-Receptor Type 11 - chemistry | Pyrimidines - pharmacology | Antineoplastic Agents - chemistry | Piperidines - chemical synthesis | Pyrazines - chemical synthesis | Pyrazines - chemistry | Animals | High-Throughput Screening Assays | Mice, Nude | Pyrazines - pharmacokinetics | Allosteric Site | Cell Line, Tumor | Pyrimidines - pharmacokinetics | Protein Conformation | Pyrazines - pharmacology | Index Medicus | inhibitors | INORGANIC, ORGANIC, PHYSICAL, AND ANALYTICAL CHEMISTRY | amines | inhibition | conformation | peptides and proteins | 60 APPLIED LIFE SCIENCES
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
3. Full Text From Acylethynylpyrroles to Pyrrolo[1,2-a]pyrazines in One Step
by Sagitova, E. F and Sobenina, L. N and Trofimov, B. A
Russian journal of organic chemistry, ISSN 1070-4280, 02/2020, Volume 56, Issue 2, pp. 225 - 233
Pyrazines | Pyrroles
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
4. Full Text Effect of Sitagliptin on Cardiovascular Outcomes in Type 2 Diabetes
by Green, Jennifer B and Bethel, M. Angelyn and Armstrong, Paul W and Buse, John B and Engel, Samuel S and Garg, Jyotsna and Josse, Robert and Kaufman, Keith D and Koglin, Joerg and Korn, Scott and Lachin, John M and McGuire, Darren K and Pencina, Michael J and Standl, Eberhard and Stein, Peter P and Suryawanshi, Shailaja and Van de Werf, Frans and Peterson, Eric D and Holman, Rury R and TECOS Study Grp and TECOS Study Group
The New England journal of medicine, ISSN 0028-4793, 07/2015, Volume 373, Issue 3, pp. 232 - 242
Medicine, General & Internal | Life Sciences & Biomedicine | General & Internal Medicine | Science & Technology | Glycated Hemoglobin A - analysis | Hypoglycemic Agents - therapeutic use | Triazoles - adverse effects | Double-Blind Method | Follow-Up Studies | Administration, Oral | Humans | Kaplan-Meier Estimate | Hospitalization - statistics & numerical data | Pyrazines - therapeutic use | Cardiovascular Diseases - complications | Diabetes Mellitus, Type 2 - blood | Heart Diseases - etiology | Heart Diseases - epidemiology | Pyrazines - adverse effects | Cardiovascular Diseases - mortality | Sitagliptin Phosphate | Diabetes Mellitus, Type 2 - drug therapy | Drug Therapy, Combination | Heart Failure - etiology | Hypoglycemic Agents - adverse effects | Diabetes Mellitus, Type 2 - complications | Triazoles - therapeutic use | Type 2 diabetes | Care and treatment | Usage | Clinical trials | Influence | Sitagliptin | Dosage and administration | Cardiovascular diseases | Myocardial infarction | Cerebral infarction | Stroke | Inhibitor drugs | Peptidase | Diabetes mellitus | Pancreatitis | Cardiovascular disease | Angina | Side effects | Pancreatic cancer | Hemoglobin | Diabetes | Health risk assessment | Drug therapy | Diabetes mellitus (non-insulin dependent) | Heart diseases | Index Medicus | Abridged Index Medicus
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
5. Full Text Selexipag for the Treatment of Pulmonary Arterial Hypertension
by Sitbon, Olivier and Channick, Richard and Chin, Kelly M and Frey, Aline and Gaine, Sean and Galiè, Nazzareno and Ghofrani, Hossein-Ardeschir and Hoeper, Marius M and Lang, Irene M and Preiss, Ralph and Rubin, Lewis J and Di Scala, Lilla and Tapson, Victor and Adzerikho, Igor and Liu, Jinming and Moiseeva, Olga and Zeng, Xiaofeng and Simonneau, Gérald and McLaughlin, Vallerie V and GRIPHON Investigators
The New England journal of medicine, ISSN 0028-4793, 12/2015, Volume 373, Issue 26, pp. 2522 - 2533
Medicine, General & Internal | Life Sciences & Biomedicine | General & Internal Medicine | Science & Technology | Hypertension, Pulmonary - mortality | Double-Blind Method | Drug Administration Schedule | Humans | Middle Aged | Kaplan-Meier Estimate | Hospitalization - statistics & numerical data | Male | Pyrazines - therapeutic use | Disease Progression | Prodrugs - adverse effects | Acetamides - therapeutic use | Pyrazines - adverse effects | Acetamides - adverse effects | Female | Aged | Hypertension, Pulmonary - drug therapy | Prodrugs - therapeutic use | Hypertension, Pulmonary - complications | Clinical trials | Usage | Drug therapy | Pulmonary hypertension | Hypertension | Headache | Jaw | Endothelin | Pulmonary arteries | Diarrhea | Nausea | Prostacyclin | Patients | Pain | Circulatory system | Phosphodiesterase | Fees & charges | Substance abuse treatment | Statistical analysis | Committees | Drug dosages | Pharmaceuticals | Index Medicus | Abridged Index Medicus
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
6. Sitagliptin: A review of its use in patients with type 2 diabetes mellitus
by Plosker, Greg L
Drugs (New York, N.Y.), ISSN 0012-6667, 2014, Volume 74, Issue 2, pp. 223 - 242
Pharmacology & Pharmacy | Toxicology | Life Sciences & Biomedicine | Science & Technology | Triazoles - administration & dosage | Triazoles - adverse effects | Dipeptidyl-Peptidase IV Inhibitors - adverse effects | Dipeptidyl-Peptidase IV Inhibitors - therapeutic use | Humans | Pyrazines - administration & dosage | Pyrazines - therapeutic use | Dipeptidyl-Peptidase IV Inhibitors - pharmacology | Dipeptidyl-Peptidase IV Inhibitors - administration & dosage | Triazoles - pharmacology | Dipeptidyl-Peptidase IV Inhibitors - pharmacokinetics | Pyrazines - pharmacokinetics | Pyrazines - adverse effects | Triazoles - pharmacokinetics | Sitagliptin Phosphate | Diabetes Mellitus, Type 2 - drug therapy | Drug Therapy, Combination | Pyrazines - pharmacology | Drug Combinations | Triazoles - therapeutic use
Journal Article
Details down arrow
7. Full Text Selective inhibition of FLT3 by gilteritinib in relapsed or refractory acute myeloid leukaemia: a multicentre, first-in-human, open-label, phase 1–2 study
by Perl, Alexander E, MD and Altman, Jessica K, MD and Cortes, Jorge, MD and Smith, Catherine, MD and Litzow, Mark, MD and Baer, Maria R, MD and Claxton, David, Prof and Erba, Harry P, Prof and Gill, Stan, PhD and Goldberg, Stuart, MD and Jurcic, Joseph G, Prof and Larson, Richard A, Prof and Liu, Chaofeng, PhD and Ritchie, Ellen, MD and Schiller, Gary, MD and Spira, Alexander I, MD and Strickland, Stephen A, MD and Tibes, Raoul, MD and Ustun, Celalettin, MD and Wang, Eunice S, Prof and Stuart, Robert, Prof and Röllig, Christoph, MD and Neubauer, Andreas, Prof and Martinelli, Giovanni, Prof and Bahceci, Erkut, MD and Levis, Mark, Dr
The lancet oncology, ISSN 1470-2045, 2017, Volume 18, Issue 8, pp. 1061 - 1075
Hematology, Oncology and Palliative Medicine | Life Sciences & Biomedicine | Oncology | Science & Technology | fms-Like Tyrosine Kinase 3 - antagonists & inhibitors | Recurrence | Aniline Compounds - pharmacology | Aniline Compounds - blood | Humans | Middle Aged | Blood Platelets | Male | Antineoplastic Agents - therapeutic use | Pyrazines - therapeutic use | fms-Like Tyrosine Kinase 3 - metabolism | fms-Like Tyrosine Kinase 3 - genetics | Retreatment | Maximum Tolerated Dose | Antineoplastic Agents - blood | Leukemia, Myeloid, Acute - drug therapy | Female | Aged | Antineoplastic Agents - pharmacology | Aniline Compounds - therapeutic use | Phosphorylation - drug effects | Pyrazines - pharmacology | Pyrazines - blood | Leukemia, Myeloid, Acute - genetics | Relapse | Diseases | Analysis | Index Medicus
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
8. Full Text Acalabrutinib (ACP-196) in Relapsed Chronic Lymphocytic Leukemia
by Byrd, John C and Harrington, Bonnie and O’Brien, Susan and Jones, Jeffrey A and Schuh, Anna and Devereux, Steve and Chaves, Jorge and Wierda, William G and Awan, Farrukh T and Brown, Jennifer R and Hillmen, Peter and Stephens, Deborah M and Ghia, Paolo and Barrientos, Jacqueline C and Pagel, John M and Woyach, Jennifer and Johnson, Dave and Johnson, Amy J and Huang, Jane and Wang, Xiaolin and Kaptein, Allard and Lannutti, Brian J and Covey, Todd and Fardis, Maria and McGreivy, Jesse and Hamdy, Ahmed and Rothbaum, Wayne and Izumi, Raquel and Diacovo, Thomas G and Furman, Richard R
The New England journal of medicine, ISSN 0028-4793, 01/2016, Volume 374, Issue 4, pp. 323 - 332
Medicine, General & Internal | Life Sciences & Biomedicine | General & Internal Medicine | Science & Technology | Recurrence | Benzamides - pharmacokinetics | Humans | Middle Aged | Pyrazines - administration & dosage | Male | Antineoplastic Agents - administration & dosage | Leukemia, Lymphocytic, Chronic, B-Cell - genetics | Protein Kinase Inhibitors - adverse effects | Diarrhea - chemically induced | Dose-Response Relationship, Drug | Benzamides - administration & dosage | Antineoplastic Agents - adverse effects | Female | Antineoplastic Agents - pharmacokinetics | Benzamides - adverse effects | Headache - chemically induced | Chromosome Deletion | Protein Kinase Inhibitors - pharmacokinetics | Administration, Oral | Disease-Free Survival | Protein Kinase Inhibitors - administration & dosage | Agammaglobulinaemia Tyrosine Kinase | Pyrazines - pharmacokinetics | Pyrazines - adverse effects | Aged | Leukemia, Lymphocytic, Chronic, B-Cell - drug therapy | Protein-Tyrosine Kinases - antagonists & inhibitors | Antimitotic agents | Treatment outcome | Usage | Care and treatment | Safety and security measures | Lymphocytic leukemia | Analysis | Clinical trials | Pharmacology | Dosage and administration | Pharmacokinetics | Antineoplastic agents | Tyrosine | Headache | Pharmacodynamics | Transformation | Chronic lymphatic leukemia | Inhibitor drugs | Leukemia | Diarrhea | Chromosome deletion | Lymphatic leukemia | Kinases | Lymphoma | Bruton's tyrosine kinase | Patients | Clonal deletion | Safety | Drug therapy | Lymphocytosis | Protein-tyrosine kinase | Chromosome 17 | Index Medicus | Abridged Index Medicus
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights